XNAS · Drug Manufacturers - General
Last stored close · Sep 18, 2026
Close · Sep 18, 2026
$385.65+1.55%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
62/100
Positive
Score components
TickerWhale View
AMGEN scores 62 out of 100 overall, which we rate positive. Technical is its strongest area and Risk its weakest.
What helps
- Technical
- Quality & growth
- Valuation
What to watch
- Risk
Quality & growth
30%76Strong
- Revenue growth 9.1%
- EPS growth 31.7%
Valuation
25%55Moderate
- P/E 24.0
- EV/Sales 6.6
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
#57 by market cap in our coverage · ~31,500 employees · Listed 1983-06-17 · www.amgen.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#43 / 139sector rank by TickerWhale Score
TickerWhale Score 62 vs sector average 55.1 (+6.9)
Revenue growth (industry)Top 27%
Gross margin (industry)Top 82%
Return on equity (industry)Top 10%
P/E (industry)Cheaper than 80%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
79/100Strong vs universe
Ranks 79th of 100 covered names on our technical composite — the composite itself scores 63/100 · 25% of the TickerWhale Score
Classic chart indicators
Sell
2 buy · 4 sell · 2 neutral of 8 votes
TickerWhale rates AMGN's technical setup strong — 79th percentile of the covered universe. Classic chart indicators lean sell — they read this stock on its own over days, where our score ranks it against every covered name over months, so the two often part company.
Moving averages
3 / 9constructive
- vs 200-day+7.0%
- vs 50-day-3.7%
Momentum
Mixed
- RSI (14)40 · neutral
- Stochasticbuy
- CCIneutral
- Williams %Rbuy
Trend
Weak
- ADX (14) trend strength33· trending
- MACD (12,26,9)sell(histogram -6.008)
How the classic verdict is reached
Moving averages (9) agree on sell — 3 buy vs 6 sell — and carry one vote between them.
Oscillators (7) vote individually: 2 buy · 3 sell · 2 neutral.
Result — 2 buy vs 4 sell of 8 votes = Sell. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-09-18 · revised_latestValuation multiples
- P/E (TTM)24.0
- P/S (TTM)5.5
- P/B17.9
- EV/EBITDA—
- EV/Sales6.6
- PEG0.76
Profitability & returns
- Gross margin69.5%
- Net margin22.9%
- ROE83.8%
- Debt/Equity4.90
Growth
- Revenue growth (YoY)9.1%
- EPS growth (YoY)31.7%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $209.8B
Fundamentals history
Reported statement totals across recent periods.
| Metric | Dec '25 | Dec '24 | Dec '23 |
|---|---|---|---|
| Revenue | $36.8B | $33.4B | $28.2B |
| Gross profit | $24.7B | $20.6B | $19.7B |
| Operating income | $9.1B | $7.3B | $7.9B |
| Net income | $7.7B | $4.1B | $6.7B |
| EPS (diluted) | $14.23 | $7.56 | $12.49 |
| Free cash flow | $8.1B | $10.4B | $7.4B |
| Cash | $9.1B | $12.0B | $10.9B |
| Total debt | $54.6B | $60.1B | $64.6B |
| Equity | $8.7B | $5.9B | $6.2B |
| Net debt | $45.5B | $48.1B | $53.7B |
| Debt / equity | 6.31 | 10.23 | 10.37 |
| Liabilities / assets | 0.90 | 0.94 | 0.94 |
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: MU →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| AMGNCurrentAMGEN | 62 | 63 | 24.0 | — | 17.9 | 6.6 | $385.65 | +1.55% | +9.1% | ||
| EXELExelixis | 81 | 80 | 17.6 | — | 8.2 | 6.1 | $58.36 | -0.22% | +9.2% | ||
| INCYIncyte | 81 | 76 | 16.2 | — | 4.1 | 3.8 | $125.31 | -1.81% | +26.9% | ||
| ACADAcadia Pharmaceuticals | 80 | 63 | 12.4 | — | 3.6 | 3.8 | $27.29 | -0.58% | +11.8% | ||
| OSCROscar Health Inc - | 78 | 67 | 19.5 | — | 5.2 | 0.5 | $32.13 | +0.47% | +43.1% | ||
| TGTXTG Therapeutics | 77 | 73 | 20.3 | — | 14.8 | 11.5 | $56.87 | +0.71% | +76.1% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.